Pipeline file · status, dated and sourced

CagriSema in 2026: not approved, under review — the status file, the trial honesty, and what to do while you wait

The regulatory status, exactly — filed, reviewing, undated

The verifiable sequence: NDA submitted December 18, 2025 for chronic weight management (BMI ≥30, or ≥27 with a weight-related comorbidity), built on the REDEFINE-1 and REDEFINE-2 pivotal program; the FDA’s standard clock makes a Q4-2026 decision window the consistent company guidance; and as of mid-2026 reporting, neither the agency nor the company has published a PDUFA action date, no advisory committee has been announced, and no approval has issued. Separately: the type-2-diabetes indication hasn’t been filed yet (company statements point to a later, separate approach on that pathway), and no European or UK submissions for weight management were confirmed in the same reporting. Reading rule for this entire topic: a filed application is a question, not an answer — outcomes include approval as filed, approval with a narrower label, requests for more information, or delay — and the difference between those futures is worth thousands of dollars and months of planning, which is why this page carries its date in the byline and the regulatory file’s read-the-docket-not-the-headlines discipline applies verbatim.

What CagriSema is — and why the combo idea matters

CagriSema pairs the semaglutide you know with cagrilintide, a long-acting analog of amylin — the pancreatic hormone co-secreted with insulin that signals satiety through pathways distinct from GLP-1’s. The design bet: two complementary appetite systems engaged at once beat one, without inventing a new molecule for each mechanism (contrast tirzepatide — a single molecule hitting GLP-1 and GIP receptors — and the triple-agonist approach retatrutide’s tracker follows). If approved, it would be the first once-weekly GLP-1/amylin combination — a genuine mechanism milestone. The class texture rides along: GI side effects lead every incretin-family profile, the combined GI burden of two satiety agents is exactly what reviewers will read closely, and none of the familiar caveats — titration ladders, lean-mass protection, discontinuation regain — gets repealed by adding a second hormone. Mechanism is why this drug is exciting; mechanism is never, by itself, why a patient should wait for it — that math comes two sections down.

The trial record, honestly — including the result the hype skips

The headline numbers are real: REDEFINE-1’s ~22.7% average at 68 weeks among participants who stayed on treatment (a “trial-product” style estimand — the idealized-adherence read; the everyone-counted figure ran lower at ~20.4% versus ~14.9% for semaglutide alone in the same framework), with ~60% of adherent patients at ≥20% loss and ~23% reaching ≥30% — territory previously reserved for surgery. REDEFINE-2’s ~15.7% in type-2 diabetes fits the class pattern of damped diabetic-population results. Then the February 2026 result that separates honest coverage from fan coverage: REDEFINE-4 put CagriSema head-to-head against tirzepatide 15 mg and — despite ~23% at 84 weeks — missed its prespecified noninferiority endpoint. Two implications, held together like adults: CagriSema’s absolute efficacy is elite, and the incumbent it needs to displace didn’t get displaced on the primary statistical question its own trial asked — a nuance with real consequences for launch positioning, payer leverage, and the premium pricing combination therapies are widely expected to carry. Also worth filing: the December NDA predates REDEFINE-4 and rests on the placebo-controlled program — so the approval question and the beats-tirzepatide question are legally separate, and conflating them is how comment sections stay wrong. Cross-trial rules from the reread file apply to every number in this paragraph.

The scam perimeter — why “buy CagriSema online” is always a red flag

Here’s the sentence that protects wallets: because CagriSema is unapproved, there is no legal U.S. access outside enrolled clinical trials — not by prescription, and not by compounding. The compounding lane that exists for semaglutide and tirzepatide runs on specific legal foundations tied to approved drugs; an unapproved fixed-dose combination has no such lane, so “compounded CagriSema” is a contradiction in terms — and the vials sold under that name (or as “cagrilintide blends”) on research-chemical sites are unregulated products with no prescriber, no named pharmacy, no batch COA that means anything, marketed to exactly the audience this hype cycle creates. The filter file’s standing disqualifiers apply at full strength, and the trial-access truth is the only clean alternative: legitimate participation runs through registered studies on clinicaltrials.gov — free, supervised, and the actual way early access works. Anyone selling you tomorrow’s molecule today is selling you something else entirely.

The working ladder today — the math against waiting

The waiting-for-CagriSema calculus collapses under its own timeline: a Q4-2026 decision window means a launch measured in additional months even in the good scenario, at a combination-therapy premium nobody has priced publicly — while the therapy that just held the noninferiority line is available now: audited compounded tirzepatide at $139–$169/month flat, dose-proof, month-to-month (the audited tirzepatide ladder, available now ↗ — compounded; same active ingredient as brand Zepbound/Mounjaro; not FDA-approved as finished drugs), with the brand lanes ($50 Bridge / ~$25 card / TrumpRx cash) layered per your coverage. A year on a working ~20%-class therapy beats a year of waiting for a ~23%-class maybe — and the month-to-month structure means an actual CagriSema approval costs you nothing to pivot toward: no prepay stranded, no contract to escape, just the standard switching file run with real prices when real prices exist. That’s the same structural-readiness logic this site applies to regulatory weather, pointed at pipeline weather: position for optionality, act on what’s approved, and let the docket — not the hype — schedule your next decision.

The four-item watchlist — real signals only

One: a published PDUFA date or advisory-committee announcement — the first hard calendar anyone will actually have. Two: the decision itself and the label’s scope — indication breadth, titration schedule, and any GI-profile language that shapes real-world use. Three: launch pricing and program structure — list, savings-card design, and whether the Bridge/TrumpRx architecture extends to it (nothing exists today; anyone quoting a price is guessing). Four: the diabetes-pathway filing — a separate regulatory track with its own clock. This page updates on those events and ignores the rest; between updates, the retatrutide tracker covers the other pipeline giant, and your annual review covers you.

FAQ

Is CagriSema FDA-approved?

No — as of August 2026 it remains under FDA review. The NDA was filed December 18, 2025; company guidance points to a Q4-2026 decision, and no PDUFA date has been publicly confirmed.

How much weight do people lose on CagriSema?

REDEFINE-1 reported ~22.7% average at 68 weeks among adherent participants (~20.4% in the everyone-counted framework vs ~14.9% for semaglutide alone); REDEFINE-2 in type-2 diabetes averaged ~15.7%; REDEFINE-4 reported ~23% at 84 weeks head-to-head but missed its noninferiority endpoint versus tirzepatide 15 mg.

Can I buy CagriSema or compounded CagriSema now?

No legal route exists outside registered clinical trials — and no legitimate compounded version can exist for an unapproved combination, so anything sold as “CagriSema” online is an unregulated research-chemical product. Trial enrollment via clinicaltrials.gov is the only clean access path.

Should I wait for CagriSema instead of starting tirzepatide?

The math says no for most: a Q4-2026 decision window plus launch lag versus a ~20%-class therapy available today at an audited $139–$169 flat — on month-to-month structure that makes any future pivot free. Waiting is a strategy only hype prices as free.